The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2015
Filed:
Oct. 31, 2011
Applicants:
Jagdeep Nanchahal, Richmond, GB;
Kim Suzanne Midwood, London, GB;
Inventors:
Jagdeep Nanchahal, Richmond, GB;
Kim Suzanne Midwood, London, GB;
Assignee:
Isis Innovation Limited, Oxford, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 31/00 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 31/00 (2013.01); A61K 45/06 (2013.01); C07K 16/241 (2013.01); A61K 38/00 (2013.01);
Abstract
Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-α antagonist. TNF-α antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.